Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Borneo Journal Of Pharmascientech

Rendemen dan Skrining Fitokimia Simplisia Daun Bayam (Amaranthus viridis) Norhayati; Rizaldi, Gusti; Noorwina, Syifa; Anida
BORNEO JOURNAL OF PHARMASCIENTECH Vol 8 No 1 (2024): Borneo Journal of Pharmascientech
Publisher : Universitas Borneo Lestari

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51817/bjp.v8i1.522

Abstract

Indonesia is rich in biodiversity. One of the plants that grows widely in Indonesia is spinach (Amaranthus viridis). The aim of this research was to determine the secondary metabolite content of the ethanol extract of spinach leaves (A. viridis) qualitatively. This research consisted of 2 stages. The first stage is making simplicia and the second stage is screening phytochemical simplicia. The yield obtained from making simplicia was 20.83%. Based on the results, it can be concluded that spinach leaves (A. viridis) contain secondary metabolites of alkaloids, tannins, phenols, and saponins. The suggestion for this research is that the secondary metabolites can be isolated and then continued with activity tests.
Studi in silico tentang naringin sebagai reseptor anti-HER-2 dalam pengobatan kanker payudara Abdurrahman, Abdurrahman; Rijal, Muh. Agus Syamsur; Yusuf, Helmy; Norhayati; Rizaldi, Gusti
BORNEO JOURNAL OF PHARMASCIENTECH Vol 8 No 2 (2024): Borneo Journal of Pharmascientech
Publisher : Universitas Borneo Lestari

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51817/bjp.v8i2.535

Abstract

Overexpression of Human Epidermal Receptor-2 (HER-2) is the cause of the development of breast cancer, so HER-2 can be a target for anticancer therapy. Trastuzumab is the drug of choice in inhibiting the HER-2 receptor and tyrosine kinase, but the weakness of this drug is that drug resistance can occur. Naringin has potential as a breast cancer therapy. The research aims to determine the inhibiting overexpression of the HER-2 receptor by naringin using in silico method. Molecular docking has been carried out by optimizing naringin and trastuzumab, preparing the HER-2 protein target (PDB ID 3PP0), validating the molecular docking protocol, and docking naringin and trastuzumab on HER-2. The research produced a binding energy of -8,66 kcal/mol, while the binding energies of the original ligand and trastuzumab to HER-2 were -9,94 kcal/mol and -5,87 kcal/mol, respectively. The binding energy shows that naringin has potential as an anti-breast cancer agent as indicated by its stronger affinity for HER2.